about
Control of cleavage site selection during mRNA 3' end formation by a yeast hnRNP.The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.Molecular pathology of Lewy body diseases.Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents.A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia.The first genetic biomarker for dementia with Lewy bodies.New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies.Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Córdoba (southern Spain).Cystathionine beta synthase as a risk factor for Alzheimer disease.Genetic contribution to aging: deleterious and helpful genes define life expectancy.Apolipoprotein E genotypes and age at onset of Parkinson's disease.Parkin and synphilin-1 isoform expression changes in Lewy body diseases.A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging.Neuropsychiatric symptoms and intelligence quotient in autosomal dominant Segawa disease.Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease.APOE-related frequency of cognitive and noncognitive symptoms in dementia.GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies.Alpha- and beta-synuclein expression in Parkinson disease with and without dementia.Cystatin C is differentially involved in multiple system atrophy phenotypes.APOE epsilon 4 allele frequency in Alzheimer's disease and vascular dementia in the Spanish population.Behavioral changes associated with different apolipoprotein E genotypes in dementia.Alzheimer's disease and the cystatin C gene polymorphism: an association study.Identification of a protective allele against Alzheimer disease in the APOE gene promoter.Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies.The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease.Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder.[Relationship between COMT gene genotypes and severity of fibromyalgia].Simpson-Golabi-Behmel Syndrome Type 1 and Hepatoblastoma in a Patient With a Novel Exon 2-4 Duplication of theGPC3GenePrimary Renal Cell Carcinoma in a Transplanted Kidney: Genetic Evidence of Recipient OriginIdentification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseasesThe Th1/E47cs-G apolipoprotein E (APOE) promoter allele is a risk factor for Alzheimer disease of very later onsetCerebrovascular Changes Associated with Interleukin-1? (IL-1?) and Histamine (HA) Levels in Alzheimer's DiseaseComprehensive proteomic profiling of plasma-derived Extracellular Vesicles from dementia with Lewy Bodies patientsExploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodiesGlucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brainAge at onset: an essential variable for the definition of genetic risk factors for sporadic Alzheimer's disease
P50
Q33890209-2064FE13-89DC-4873-8C7E-53FFD892A509Q37320265-2C8A2EC5-4613-4D70-A673-BC3B128CDA32Q37462203-DC280B96-9B46-4F2A-B3F7-72CC8BB0D119Q41117495-D2D1110F-9342-42AE-BFF9-89E7B6418DBAQ42715112-6B1E8773-7783-4351-85C2-1797572D956BQ43528737-B838C3F8-D748-4E69-BDC2-25ADEC97ACE5Q44603447-7A4B8AFF-5A17-4BB7-B50A-F33C965BB9FDQ45142189-4A9369B8-9C38-4C9D-9426-149F9FDDF0BBQ45966257-C4D32FE4-D8B5-4D94-86C4-32EA55FB7205Q46563533-34A308B5-501A-421A-86B7-4A69E0C8BCCBQ46884733-0C11586A-27E9-4978-8A10-38E693AF44FDQ47671550-FB07CC81-695F-42A4-8723-4989C7395E70Q48184383-E42DE798-532F-409D-BEAA-A72C42538198Q48227930-4AF94E9C-62FB-49D9-869E-593C6D55E6FEQ48303791-499E0714-FB57-40D8-BB33-076DE02AF15FQ48429674-0CF20421-E556-4CC8-B6B2-A1699CF78692Q48833246-54AF7D9A-FB57-4367-B1AD-776FAE7D6E26Q48835738-046370AD-74F4-4F20-9268-922257497384Q49155731-1C551DC4-E41C-4E53-8FA5-68087C423E15Q50477602-E72ACABE-3666-4EED-94E4-62BA45F0928BQ53219712-0A99DC89-C2CE-456C-8D99-152DFDBC3D48Q53219864-0D49E1BB-5E73-430B-87C2-7A838E45216DQ53245107-CC2A0ED8-AFF0-4390-981E-2EB181A829FDQ53249830-2B612682-4B86-48DB-B7FF-17DAB3A3CAD5Q53265500-8E40BCE3-368F-4418-BB0F-6D1BB1C1A044Q53313817-81B24A3F-A394-40A8-84DE-A90EFE55D9BDQ53339940-CA67F9F8-DFE6-44C4-9DDB-5659BC66565FQ53392035-EAE0A7B5-F37B-4BC1-9246-B3D82542412DQ53445747-2997416D-49CC-4289-ADCB-D8D3D3389264Q54594660-55ADA492-8DBC-48C8-8311-74C1CA6734C8Q62746661-0F808075-1803-415B-BD18-836AF6DE42B5Q62746715-D4B9C985-9A3C-4A44-867C-9E5CD9BDC9D9Q62746751-5FD4204F-D12D-42DD-9864-3603C5D58288Q62746899-1E532823-21C2-4E46-B9B3-FC541611CF88Q62746980-1F79C2E3-C743-429F-8549-003797315E8AQ90134438-D9A4123C-5162-422D-9EB6-F8A1B4B2A954Q90582607-7994B2EE-4905-43D4-A147-55A429EC9B5CQ92217532-4627F5B4-7E39-43E6-A64A-FF49510652A3Q95811787-DED9E2C2-9E74-4EAC-8639-81ADB3D50B9A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katrin Beyer
@ast
Katrin Beyer
@en
Katrin Beyer
@es
Katrin Beyer
@nl
Katrin Beyer
@sl
type
label
Katrin Beyer
@ast
Katrin Beyer
@en
Katrin Beyer
@es
Katrin Beyer
@nl
Katrin Beyer
@sl
prefLabel
Katrin Beyer
@ast
Katrin Beyer
@en
Katrin Beyer
@es
Katrin Beyer
@nl
Katrin Beyer
@sl
P1053
C-3001-2017
P106
P1153
35498475200
P21
P31
P3829
P496
0000-0001-8905-1514